In addition, a small-molecule JAK kinase inhibitor inhibits proliferation of MPLW515L-transformed cells, suggesting that targeted inhibition of JAK-STAT signaling may be an effective therapy for bothJAK2V617F-positive andMPLW515L-positive MPD. The gene discussed is SOAT1; the disease is myeloproliferative disorder.